These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17391142)

  • 1. Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells.
    Gao R; Ustinov J; Korsgren O; Otonkoski T
    Am J Transplant; 2007 Apr; 7(4):1021-6. PubMed ID: 17391142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories.
    Hyder A; Laue C; Schrezenmeir J
    Toxicol In Vitro; 2005 Jun; 19(4):541-6. PubMed ID: 15826812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets.
    Paty BW; Harmon JS; Marsh CL; Robertson RP
    Transplantation; 2002 Feb; 73(3):353-7. PubMed ID: 11884930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.
    Johnson JD; Ao Z; Ao P; Li H; Dai LJ; He Z; Tee M; Potter KJ; Klimek AM; Meloche RM; Thompson DM; Verchere CB; Warnock GL
    Cell Transplant; 2009; 18(8):833-45. PubMed ID: 19500470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation.
    Bhorade SM; Jordan A; Villanueva J; Yu A; Kramer H; Vigneswaran WT; Garrity ER
    Am J Transplant; 2003 Dec; 3(12):1570-5. PubMed ID: 14629288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
    Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
    N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells.
    Bussiere CT; Lakey JR; Shapiro AM; Korbutt GS
    Diabetologia; 2006 Oct; 49(10):2341-9. PubMed ID: 16896936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study.
    ter Meulen CG; van Riemsdijk I; Hené RJ; Christiaans MH; Borm GF; van Gelder T; Hilbrands LB; Weimar W; Hoitsma AJ
    Am J Transplant; 2004 May; 4(5):803-10. PubMed ID: 15084178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.
    Sheashaa HA; Bakr MA; Fouda MA; El-Dahshan KF; Ismail AM; Sobh MA; Ghoneim MA
    Int Urol Nephrol; 2007; 39(1):317-9. PubMed ID: 17333530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
    Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration.
    Waller JR; Brook NR; Bicknell GR; Murphy GJ; Nicholson ML
    Transplant Proc; 2005; 37(1):164-6. PubMed ID: 15808582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil.
    Brunet M; Cirera I; Martorell J; Vidal E; Millán O; Jiménez O; Rojo I; Londoño MC; Rimola A
    Transplantation; 2006 Feb; 81(4):541-6. PubMed ID: 16495801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.
    Gottlieb PA; Quinlan S; Krause-Steinrauf H; Greenbaum CJ; Wilson DM; Rodriguez H; Schatz DA; Moran AM; Lachin JM; Skyler JS;
    Diabetes Care; 2010 Apr; 33(4):826-32. PubMed ID: 20067954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model.
    Montgomery SP; Mog SR; Xu H; Tadaki DK; Hirshberg B; Berning JD; Leconte J; Harlan DM; Hale D; Kirk AD
    Am J Transplant; 2002 Apr; 2(4):381-5. PubMed ID: 12118862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells.
    Polastri L; Galbiati F; Bertuzzi F; Fiorina P; Nano R; Gregori S; Aldrighetti L; Pozza G; Secchi A; Adorini L; Davalli AM
    Acta Diabetol; 2002 Dec; 39(4):229-33. PubMed ID: 12486498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
    Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.